产品介绍:

哌柏西利（Palbociclib，又译为：帕博西尼）是全球首个细胞周期蛋白依赖性激酶（CDK）4/6抑制剂，适用于治疗激素受体（HR）阳性、人表皮生长因子受体2（HER2）阴性的局部晚期或转移性乳腺癌，应与芳香化酶抑制剂联合使用作为绝经后女性患者的初始内分泌治疗。

乳腺癌是严重威胁全世界女性健康的第一大恶性肿瘤，晚期乳腺癌的形势更为严峻，总体中位生存期仅有2-3年，5年生存率仅约20%。

CDK4/6抑制剂是近年来热门的抗癌“神药”，正在迅速改变HR + HER2-晚期乳腺癌的治疗格局，有效地克服或延迟内分泌抵抗的出现，为晚期患者争取更多的生存时间。

基于II期研究PALOMA-1，2015年2月3日美国FDA加速批准了哌柏西利联合来曲唑用于绝经后 ER+/HER2-晚期乳腺癌的一线治疗。2016年2月19日美国FDA根据一项随机对照III期研究（PALOMA-3）又批准了哌柏西利联合氟维司群用于既往内分泌治疗失败的HR+/HER2- 绝经后晚期乳腺癌。

由于优秀的疗效及安全性，哌柏西利至今已在全球80多个国家和地区获批上市。2018年7月31日，中国药监局批准了该药在华上市，是哌柏西利第87个获准上市的国家，也是中国10年来晚期乳腺癌唯一突破性创新疗法，因此备受关注。

碧康制药生产的Palbonix是哌柏西利是获得孟加拉政府监管机构批准合法生产的仿制药。

碧康制药由欧洲财团参与投资，是南亚地区唯一执行欧盟技术规范，并且在孟加拉两大证券交易所主板上市的大型制药企业，产品符合欧洲药典和美国药典标准。

相比其他来源不清晰的所谓同一种仿制药，即使其主要成份含量与碧康产品相接近，但由于不具备严格规范的GMP标准生产场所和政府部门的严格监管，其产品中影响药物吸收率的溶出度和生物利用度也与碧康产品具有很大差异。

为保证用药安全，敬请谨慎选择！

适应症:

用于激素受体（HR）阳性，人表皮生长因子受体2（EFGR2）阴性的进展性或转移性乳腺癌，可联合用于以下情形：

1、与来曲唑联用，用于治疗绝经后女性患者的雌激素受体阳性（ER+）及人表皮生长因子受体阴性(Her2)的晚期乳腺癌；

2、联合氟维司群，用于既往内分泌治疗失败的HR/Her2绝经后晚期乳腺癌。

用法与用量:

推荐起始剂量为每日1次，每次125 mg，与来曲唑联合使用，与餐同服，共21天，之后停止服药7天。

 特殊人群的使用：

哺乳妇女停药或停止哺乳。

 常见副作用：

最常见的不良反应（发生率≥10％）为白细胞减少，白细胞减少，乏力，贫血，上呼吸道感染，恶心，口腔炎，脱发，腹泻，血小板减少症，食欲下降，呕吐，无力，周围神经病变，和鼻出血。

Neocuron Injection Details:

Brand Name    : Neocuron Injection
Content            : Pancuronium Bromide
Manufacturer : Neon Laboratories Ltd.
Strength          : 4 mg/ 2 ml

Perjeta Pertuzumab Injection Wholesale Price 

PERJETA is an FDA-approved treatment for HER2-positive metastatic breast cancer. It is a targeted therapy used as part of a first-line HER2-positive metastatic breast cancer treatment plan, in combination with Herceptin (trastuzumab) and docetaxel.

Pertuzumab Perjeta

Perjeta is called a monoclonal antibody. It works by attaching to the HER2 cancer cells and blocking them from dividing and growing. It may also destroy the cancer cells or signal the body (immune system) to destroy the cancer cells.

Pertuzumab MEDICINE USES :

Pertuzumab is used with other medications to treat certain types of breast cancer that has spread to other parts of the body in patients who have not received treatment or chemotherapy. It is also used with other medications to treat early stage breast cancer in patients who will be having surgery to remove cancer. The types of cancers Perjeta is used to treat are tumors that produce more than the normal amount of a certain substance called HER2 protein.

PERTUZUMAB COMMON SIDE EFFECTS :

nausea, diarrhea; temporary hair loss; tired feeling; numbness or tingling in your hands or feet; or mild rash or itching.

Call your doctor at once if you have a serious side effect such as:

    shortness of breath (even with mild exertion), swelling, rapid weight gain;
    fever, swollen gums, painful mouth sores, pain when swallowing, skin sores, cold or flu symptoms, cough, trouble         breathing;
    easy bruising or bleeding (nosebleeds, bleeding gums); or
    pale skin, feeling light-headed, rapid heart rate, trouble concentrating.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.

PERJETA PERTUZUMAB VIAL PRECAUTIONS:

·        
Before using this
medication, tell your doctor or pharmacist your medical history, especially of:
previous cancer treatments (including radiation therapy to the chest), heart
disease, high blood pressure, a previous severe reaction to monoclonal antibody
treatment.

·        
Perjeta can make
you more likely to get infections or may worsen any current infection. Avoid contact
with people who have infections that may spread to others (such as chickenpox,
measles, flu). Consult your doctor if you have been exposed to an infection or
for more details.

·        
Do not have
immunizations/vaccinations without the consent of your doctor. Avoid contact
with people who have recently received live vaccines (such as flu vaccine
inhaled through the nose).

·        
Tell your doctor
if you are pregnant or plan to become pregnant. You should not become pregnant
while using Pertuzumab. This medication may harm an unborn baby.

·        
It is unknown if
this medication passes into breast milk. Because of the possible risk to the
infant, breast-feeding is not recommended while using this drug or for 7 months
after the last dose. Consult your doctor before breast-feeding.

This is not a complete list. Ask your health care provider for more information.

STORAGE REQUIREMENTS :

Store vials in a refrigerator at 2°C to 8°C (36°F to 46°F) until time of use. Keep vial in the outer carton in order to protect from light. DO NOT FREEZE. DO NOT SHAKE.

DRUG INTERACTIONS :

Drug interactions may change how your medications work or increase your risk for serious side effects. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor’s approval.